ORLANDO -- For type 1 diabetes patients, switching from an insulin pump or multiple daily injections to inhaled insulin (Afrezza) maintained glycemic control -- for those who used it as intended, the ...

Most of the 38 million people living with diabetes in the U.S. use daily injections or insulin pumps to keep glucose at safe levels — but new research suggests that a third option could be just as ...

A rapid-acting dry-powder inhaled insulin (Exubera), an alternative to injected insulin, currently is being reviewed by the FDA. In this industry-sponsored multicenter trial, 145 patients whose type 2 ...

This is an exciting time in the treatment of diabetes. Continuous, subcutaneous insulin infusion and continuous glucose monitoring technologies are making optimal glucose control accessible to more ...

A Prescription Drug User Fee Act target date of May 29, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License ...

ORLANDO -- Most adults with type 1 diabetes switching from an insulin pump or multiple daily injections to inhaled insulin (Afrezza) needed to increase their dose of the inhaled product to achieve ...

The pulmonary delivery of insulin may reduce the need for multiple daily subcutaneous injections of insulin for many patients with diabetes. The lungs are an attractive site for delivery of insulin ...

Diabetic patients are often advised insulin therapy. But taking multiple injections daily may feel like a nightmare for many. But to tackle this issue, inhaled insulin has been recently launched in ...

TUCSON, Ariz. (KGUN) — Diabetics have many options nowadays for their treatment plans. Afrezza is FDA-approved for adults with type 1 or type 2 diabetes as a fast-acting, mealtime insulin, but it ...

The company helping Eli Lilly and Co. develop inhaled insulin said it expects Lilly to scuttle the project next week. Massachusetts-based Alkermes Inc. said in a news release this morning that Lilly ...